Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274624 | 0.86 | TNNI3K (0.77) | TNNI3KBRAF | |
| SCHEMBL12517482 | 0.86 | TNNI3K (1.00) | TNNI3KBRAF | |
| SCHEMBL14323857 | 0.86 | TNNI3K (0.74) | TNNI3KBRAF | |
| SCHEMBL12517840 | 0.85 | TNNI3K (0.82) | TNNI3KBRAF | |
| SCHEMBL14323862 | 0.85 | TNNI3K (0.67) | TNNI3KBRAF | |
| SCHEMBL14322867 | 0.85 | TNNI3K (0.74) | TNNI3KBRAF | |
| SCHEMBL2280785 | 0.84 | TNNI3K (0.78) | TNNI3KBRAF | |
| SCHEMBL12517467 | 0.84 | BRAF (1.00) | TNNI3KBRAF | |
| SCHEMBL14323789 | 0.84 | TNNI3K (0.77) | TNNI3KBRAF | |
| SCHEMBL2276372 | 0.83 | TNNI3K (0.72) | TNNI3KBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| EP-2523559-A1 | COMPOUNDS AND METHODS | GlaxoSmithKline LLC (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | TNNI3K 2596/4885BRAF 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.